BioAro Launched LONgevity+ Bioactives Internationally
The biotech firm has expanded its healthspan-focused product line into the United States and United Kingdom markets.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Do you trust health products developed using artificial intelligence?
BioAro has officially launched its LONgevity+ bioactive products in the United States and the United Kingdom. These formulations were developed using an artificial intelligence-driven research workflow to support healthy aging.
Why it matters
The company aims to address biological pathways related to healthspan and longevity through research-backed supplements. This move marks a significant geographic expansion for the brand following its initial product launch in Dubai.
The company leverages an artificial intelligence workflow that analyzes scientific literature, molecular relationships, and biological pathways to inform its development process. This methodology integrates biotechnology research and formulation science to create its targeted product offerings.
The players
BioAro
This biotechnology firm specializes in aging and healthspan research through an AI-integrated development platform.
Dr. Anmol S. Kapoor
He is the founder of BioAro and oversees the research and development of the company's biological formulations.
Kapoor Wealth Partners
This investment firm provides the financial backing for the BioAro Drugs consumer platform.
The details
BioAro Drugs serves as the dedicated consumer platform for the new product line, which is backed by funding from Kapoor Wealth Partners. Future plans for the platform include the integration of peptide-based offerings, pharmaceutical products, and remote consultations.
Timeline
September 23, 2026: BioAro launched the LONgevity+ bioactives.
The Tech Race
The entry of AI-optimized longevity products marks a shift in the biotechnology industry toward using algorithmic analysis to target complex biological pathways. This approach represents an evolution from traditional, trial-and-error supplement formulation methods toward precision healthspan management.
Consumers in the United States and United Kingdom can now access these longevity-focused formulations directly through the BioAro Drugs online platform. Users should anticipate future site updates as the company integrates planned pharmaceutical offerings and online health consultations.
The takeaway
The intersection of artificial intelligence and formulation science is increasingly defining how personalized health products reach the global market. Readers should monitor these developments as companies transition from simple supplements toward more complex, data-driven therapeutic approaches.
Further reading
Learn more about the latest innovations in the field at Biotech.
More information
For more information on the new product line, visit the BioAro Drugs consumer health website.
Live Poll
Do you trust health products developed using artificial intelligence?
